12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Actavis, Watson deal

Watson completed its acquisition of fellow generics company Actavis for €4.3 billion ($5.5 billion) in cash. Watson said it will change its name to Actavis and adopt a new trading symbol on the NYSE, effective next year (see BioCentury, July 16).

Watson also announced management transitions in its global generic...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >